Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)

Phase III Randomized Study of R-CHOP vs Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

A Randomized Phase II Trial of Rituximab vs. Lenalidomide (Revlimid™ or CC-5013) vs. Rituximab plus Lenalidomide in Recurrent Follicular Non-Hodgkin’s Lymphoma (NHL) After Relapse from a Rituximab-Containing Combination Regimen

A Phase II Trial of Bortezomib (Velcade) plus Lenalidomide(Revlimid™ or CC-5013) for Relapsed/Refractory Mantle Cell Lymphoma

Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical
Hodgkin Lymphoma (HL)

Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma

Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Low Tumor Burden Patients with Indolent Non-Hodgkin’s Lymphoma

Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense) Therapy for Young Adult Patients (< Age 60) with Advanced Stage Diffuse Large B-Cell NHL of Low and Low-Intermediate IPI Risk, Phase II

Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin’s Lymphoma

A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin’s Lymphoma

A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging

Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease